Systemic thrombolysis in acute ischemic stroke after dabigatran etexilate reversal with idarucizumab—a case report

D Tireli, J He, MM Nordling, T Wienecke - Journal of Stroke and …, 2017 - Elsevier
Introduction Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the
anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients …

Reducing potentially avoidable tasks in a hyperacute stroke unit

D Tireli, MB Jensen - BMJ Open Quality, 2021 - bmjopenquality.bmj.com
The workflow in a stroke unit can be very high, and this is especially noticeable during
evening and night shifts, where staffing is reduced but the patient's need for frequent and …